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Introduction
Rat conditioned avoidance response (CAR) model is an 
instrumental conditioning paradigm, in which rats are 
trained to make an active motor response to avoid foot-
shock (Bolles, 1970). In a typical CAR experiment, a rat is 
placed in a two-compartment shuttle box and presented 
with a conditioned stimulus (CS, e.g., white noise), fol-
lowed by an aversive unconditioned stimulus (US, e.g., 
footshock). After several CS-US pairings, the rat typi-
cally runs from one compartment to another during the 
CS (before the onset of the US), hence, avoiding the US.
The CAR model is a well-established preclinical test 
for antipsychotic activity with high predictive validity 
(Arnt, 1982; Natesan, et al., 2006; Wadenberg, et al., 2001). 
All currently used antipsychotic drugs at the clinical rel-
evant doses, selectively suppress avoidance responding 
while leaving escape response intact. In contrast, anxi-
olytics and antidepressants do not have this selectivity. 
Thus, the antiavoidance effect is frequently used as a val-
idated behavioral index of ‘antipsychotic’ property. Most 
work in preclinical psychopharmacology has used the rat 
CAR model as a simple screening tool to identify chemi-
cal compounds with potential antipsychotic activity, and 
the majority of the work relies on the acute treatment 
effect. Little attention, however, has been paid to under-
stand the behavioral mechanisms underlying the antia-
voidance effect of antipsychotics. We recently addressed 
this issue (Li, 2007). We used a repeated drug treatment 
regimen to better mimic clinical treatment conditions 
and found that rats treated with haloperidol (HAL), ris-
peridone (RIS), or olanzapine (OLZ) daily for 7 consec-
utive days showed a progressive across-session decline 
in avoidance responding. We also found that rats pre-
viously treated with HAL and retested under the same 
dose of HAL after their avoidances recovered to the pre-
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Abstract
Antipsychotic drugs selectively suppress conditioned 
avoidance response. Using a two-way active avoid-
ance response paradigm, we examined the role of drug-
induced interoceptive state in the mediation of avoid-
ance-suppressive effect. In Experiment 1, we found that 
rats intermittently treated with olanzapine (OLZ) (1.0 
mg/kg, s.c.) or haloperidol (0.03 mg/kg, s.c.) on the 1st 
day of a 3-day cycle for seven cycles exhibited a pro-
gressive across-session decline in avoidance responding, 
despite the fact that they exhibited a comparable high 
level of avoidance responding on the 3rd day of each 
cycle during the drug-free retraining session. In Exper-
iments 2 and 3, rats that were previously treated with 
OLZ (0.5-2.0 mg/kg, s.c.) or risperidone (0.2-1.0 mg/kg) 
during the acquisition phase of avoidance conditioning 
exhibited significantly fewer avoidance responses when 
they were retested 3 weeks later to the same drug in com-
parison to rats that were previously treated with nonan-
tipsychotic drugs (chlordiazepoxide, 10 mg/kg, citalo-
pram 10 mg/kg, or sterile water). Overall, these findings 
indicate a ‘drug memory’-like mechanism that maintains 
the avoidance-suppressing effect of antipsychotics over 
time. This mechanism is likely driven by the interocep-
tive state caused by the antipsychotics, which may also 
be an important behavioral mechanism mediating the 
clinical effects of antipsychotic treatments.
Key words: conditioned avoidance response; drug mem-
ory; haloperidol; interoceptive drug state; olanzapine; 
rat; risperidone
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drug level, still showed fewer avoidances than when 
they were first tested. This finding indicates that HAL 
treatment may induce a ‘memory-like’ mechanism that 
allows the animal to ‘remember’ how to perform under 
the influence of drug in the avoidance responding sit-
uation. This ‘memory-like’ mechanism is likely driven 
by the interoceptive state caused by the antipsychotics 
(Overton, 1979; Schechter and Cook, 1975) and may play 
an important role in the maintenance of decreased avoid-
ance responding across sessions.
The notion that the drug-induced interoceptive state(s) 
may be directly involved in the antipsychotic effects 
is relatively new, although preclinical studies such as 
those based on drug discrimination and state-dependent 
learning have long recognized the distinct drug states 
induced by typical and atypical antipsychotics (Goudie, 
et al., 1998; Overton, 1979; Porter, et al., 2005; Porter, et 
al., 2000). In this study, we report three experiments that 
further examined the role of the antipsychotic-induced 
interoceptive state in the antiavoidance (antipsychotic) 
effects of antipsychotic drugs. In Experiment 1, using a 
between-subjects design and an intermittent (on-off-on) 
drug treatment regimen, we tested the effects of repeated 
HAL (0.03 mg/kg, s.c.) and OLZ (1.0 mg/kg, s.c.) treat-
ment (once every 72 h) on avoidance responding over 
seven nonconsecutive test sessions. During the ‘off’ days, 
rats were retrained drug-free to maintain a high level of 
avoidance. We found the same progressively enhanced 
disruption on avoidance responding, as we observed in 
rats tested in the consecutive schedule, despite the fact 
that they all exhibited a high level of avoidance immedi-
ately prior to each drug session (e.g. during the drug-free 
retraining sessions). In the subsequent HAL tests, when 
all the rats were tested under HAL (0.03 mg/kg, s.c.), 
those that were previously treated with OLZ showed 
significantly lower avoidance responding than did those 
that had previously received the vehicle, even though 
both groups were exposed to HAL for the first time, sug-
gesting that the antipsychotic drug state induced by OLZ 
may have some similarities to that induced by HAL. In 
Experiments 2 and 3, we examined this mechanism by 
giving naive rats various doses of OLZ (Experiment 2) or 
RIS (Experiment 3) during the acquisition phase of avoid-
ance conditioning, retrained them drug-free for a period 
of 3 weeks, and then tested their avoidance responding 
under OLZ (1.0 mg/kg, s.c.) or RIS (0.33 mg/kg, s.c.). 
We reasoned that if the antipsychotic-induced interocep-
tive drug state is one of the mechanisms that maintain 
the antiavoidance effect of antipsychotics over time, we 
should still be able to observe that rats previously treated 
with OLZ or RIS during the acquisition phase (before the 
acquisition of avoidance behavior) would still show a 
stronger response to OLZ or RIS respectively after they 
had acquired high avoidance response. Results were 
consistent with our prediction.
Materials and methods
Animals
Male Sprague-Dawley rats (226-250 g upon arrival, 
Charles River, Portage, MI) were housed two per cage, 
in 48.3 × 26.7 × 20.3 cm transparent polycarbonate cages 
lined with aspen shavings. The colony temperature was 
maintained at 21 ± 1º C with a relative humidity of 55%-
60%, with water and food available ad libitum. All behav-
ioral tests were conducted during the light phase of a 12 
h light-dark cycle (with light on between 6:00 a.m. and 
6:00 p.m.). Rats were allowed at least 1 week of habitu-
ation to the animal facility before being used in experi-
ments. All protocols were approved by the University of 
Nebraska–Lincoln Animal Care and Use Committee.
Drugs
The injection solutions of HAL (5 mg/mL, Sabex Inc, 
Quebec, Canada) and chlordiazepoxide (CDP, Sigma-
Aldrich, St. Louis, MO) were obtained by mixing drugs 
with sterile water. OLZ (Toronto Research Chemicals 
Inc, Ontario, Canada) and RIS (a gift from the NIMH 
drug supply program) were dissolved in 1%-1.5% gla-
cial acetic acid in sterile water. Citalopram (CIT, Toronto 
Research Chemicals Inc., Ontario, Canada) was dis-
solved in 0.9% physiological saline. HAL, OLZ, RIS, and 
CIT were administered subcutaneously (s.c.) 1 h before 
avoidance training or testing, whereas CDP was injected 
0.5 h before avoidance training (Li, et al., 2007).
Apparatus
Six identical two-way shuttle boxes custom designed 
and manufactured by Med Associates (St. Albans, VT) 
were used. Each box was housed in a ventilated, sound-
insulated isolation cubicle (96.52 cm W × 35.56 cm D × 
55.88–63.5 cm H). Each box was 64 cm long, 30 cm high 
(from grid floor), and 24 cm wide and was divided into 
two equal-sized compartments by a partition with an 
arch style doorway (15 cm high × 9 cm wide at base). 
A barrier (4 cm high) was placed between the two com-
partments, so the rats had to jump from one compart-
ment to the other. The grid floor consisted of 40 stain-
less-steel rods with a diameter of 0.48 cm, spaced 1.6 cm 
apart center to center, through which a scrambled foot-
shock (US, 0.8 mA, maximum duration: 5 s) was deliv-
ered by a constant current shock generator (Model ENV-
410B) and scrambler (Model ENV-412). Illumination was 
provided by two houselights mounted at the top of each 
compartment. The CS was a 76 dB white noise produced 
by a speaker (ENV 224 AMX) mounted on the ceiling of 
the cubicle, centered above the shuttle box. Background 
noise (approximately 74 dB) was provided by a ventila-
tion fan affixed at the top corner of each isolation cubicle. 
All training and testing procedures were controlled by 
Med Associates programs running on a computer.
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Avoidance conditioning and testing procedure
A regular training/testing session consisted of either 20 
or 30 trials (see below for details). Each trial started with 
the presentation of white noise (CS) for 10 s, followed by 
a continuous scrambled footshock (maximum duration 
= 5 s, 0.8 mA, US) on the grid floor. If a subject moved 
from one compartment to the other within the 10 s of 
CS presentation, it avoided the shock, and this shuttling 
response was recorded as avoidance.If the rat remained 
in the same compartment for more than 10 s and made a 
crossing upon receiving the footshock, this response was 
recorded as escape. If the rat did not respond during the 
entire presentation of the shock, the trial was terminated 
and escape failure was recorded.
Statistical analysis
The number of avoidance responses was used as the 
main dependent variable. Avoidance data from the 
repeated drug test sessions were expressed as mean 
values ± SEM and were analyzed using a factorial 
repeated measures analysis of variance (ANOVA) with 
the between-subjects factor being treatment groups (e.g. 
HAL, OLZ, RIS etc.), and the within-subjects factor being 
the drug test sessions. To identify the group difference 
on specific test sessions, one-way ANOVAs followed by 
post-hoc Tukey (HSD) tests (for more than three groups) 
or independent-samples T-tests (for two-group compar-
isons) were used. A conventional two-tailed level of sig-
nificance at the 5% level was required.
Experiment 1: Effects of repeated intermittent HAL 
(0.03 mg/kg) or OLZ (1.0 mg/kg) treatment on avoidance 
responding This experiment was designed to examine 
the role of antipsychotic-induced interoceptive state in 
the potentiation of the antiavoidance effect of repeated 
antipsychotic treatment, using an intermittent ‘on-off-
on’ 3-day treatment/test schedule. This schedule con-
sisted of seven 3-day treatment/test cycles. The first day 
was a drug treatment and CAR test session. Well-trained 
rats (>70% avoidance in the last two training sessions) 
were injected with HAL (0.03 mg/kg, s.c.), OLZ (1.0 mg/
kg, s.c.), or vehicle (sterile water) and tested in a 30-trial 
CAR session. The second day was a drug-free resting 
day, and the third day was a drug-free CAR retraining 
day when all rats were retrained in the 30-trial CAR ses-
sion. This cycle repeated for seven times. This schedule 
ensured that immediately before each cycle of drug test, 
the rats’ avoidance responding was recovered back to 
the predrug level. If the drug-induced interoceptive state 
is one of the important behavioral mechanisms underly-
ing the potentiated antiavoidance effect associated with 
repeated drug treatment, we would expect to see lower 
avoidance only during the drug test sessions, and a pro-
gressive decline in avoidance responding across the drug 
sessions. Another advantage of this schedule was that it 
minimizes the possibility of drug accumulation, so the 
observed potentiated effect could only be attributed to 
the drug cue. At the end of this intermittent schedule, all 
rats were tested under HAL (0.03 mg/kg, s.c.) for three 
consecutive sessions to examine whether previous OLZ 
experience potentiated later response to HAL as a way of 
assessing the similarity between the HAL-induced and 
OLZ-induced interoceptive states.
Experimental procedure
A total of 30 rats were first habituated to the avoid-
ance boxes for 2 days. On each day, rats were placed in 
the box and allowed to explore the entire box for 20 min. 
Rats were then trained for a total of eleven sessions (30 
trials/session) over a 17-day period. At the end of the 
training session, 23 rats had reached training criterion (at 
or above 70% avoidance, or 21 trials, by the last 2 training 
days), and they were randomly assigned to three groups 
(n =7 vehicle, n =8 HAL, n = 8 OLZ) and started the inter-
mittent ‘on-off-on’ 3-day treatment/test schedule. On 
Day 1, rats were injected with HAL (0.03 mg/kg), OLZ 
(1.0 mg/kg), or vehicle (sterile water) subcutaneously 1 
h before being placed in the apparatus and tested. The 
same procedure as used during the training was used for 
the drug testing. On Day 2, rats were left alone in their 
home cages. On Day 3, rats were retrained. This cycle 
repeated for seven times over a period of 21 days. One 
day after the end of the seventh cycle, all three groups 
were injected with HAL  (0.03 mg/kg, s.c.) and tested for 
three additional sessions.
Experiment 2: Effects of OLZ treatment (0.5, 1.0 and 2.0 
mg/kg) during the avoidance training on later avoid-
ance responding to OLZ (1.0 mg/kg) This experiment 
examined whether previous drug experience during 
the acquisition phase of CAR might persist and cause 
a potentiated OLZ response later. Forty-five rats were 
randomly assigned to five groups (n =9/ group): vehi-
cle (sterile water), OLZ 0.5, 1.0, 2.0 mg/kg, and CDP 10.0 
mg/kg. After 2 days of habituation to the CAR boxes, all 
rats were trained in a 20-trial CAR session for 7 consec-
utive days. Each daily training session started 1 h after 
the OLZ or vehicle injection, or 30 min after CDP injec-
tions. One day later, the learning effect was assessed in 
three drug-free avoidance testing sessions in which only 
the CS was presented for 20 trials (no shock US). Dur-
ing these 10 days of the training/testing period, the rat’s 
body temperature was also measured, using a probe 
(lubricated with mineral oil) inserted in the rectum (Ther-
malert TH-5, Physitemp, Clifton, NJ, USA) before and 
after each session. Because these data were not relevant to 
the question addressed here, they were not reported here 
but were reported in a separate paper (Mead, et al., 2008). 
After 3 days of resting, all rats were retrained (drug free) 
to reacquire avoidance responding in 10 sessions (30 tri-
als/ session) over 15 days. At the end of the training ses-
sion, 35 rats had reached the training criteria (at or above 
70% avoidance on the last 2 training days). These rats 
were classified into two groups: one group consisting of 
rats that were previously treated with OLZ (n = 11 of 
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27 rats, OLZ 0.5, 1.0, 2.0 mg/kg, s.c., collectively termed 
the ‘Olanzapine Experience’ group), and one group con-
sisting of rats that were previously treated with either 
vehicle orCDP (n = 13 of 18, termed the ‘No Olanzapine 
Experience’ group). They were then treated with 1.0 mg/
kg of OLZ and tested for 3 consecutive days.
Experiment 3: Effects of RIS treatment (0.2, 0.33, and 1.0 
mg/kg) during the avoidance training on later avoid-
ance responding to RIS (0.33 mg/kg) This experiment 
was identical to Experiment 2 with the following excep-
tions. First, 48 rats were used and randomly assigned to 
six groups (n = 8/group): vehicle (sterile water), RIS 0.2, 
0.33, 1.0 mg/kg, CDP 10.0 mg/kg and CIT 10.0 mg/kg. 
Second, during the seven daily CAR test sessions under 
drug and three daily CAR drug-free test sessions, all rats 
were also tested for the startle reflex immediately after 
being removed from the CAR boxes (these data were not 
relevant to this study and are not reported here). All rats 
were then retrained (drug-free) to reacquire avoidance 
responding in ten sessions (30 trials/session) over 18 days. 
After retraining, 45 rats had reached training criteria (at 
or above 70% avoidance on the last two training days). 
These rats were classified into two groups: one group 
consisting of rats that were previously treated with RIS 
(n = 22, termed the ‘Risperidone Experience’ group), and 
one group consisting of rats that were previously treated 
with either vehicle, CDP or CIT (n = 23, termed the ‘No 
Risperidone Experience’ group). They were then treated 
with 0.33 mg/kg of RIS and tested for 3 consecutive days.
Results
Experiment 1: Effects of intermittent HAL (0.03 mg/kg) or 
OLZ (1.0 mg/kg) treatment on avoidance responding
Figure 1A shows the effects of intermittent HAL and 
OLZ treatment on avoidance responding across the 
seven test cycles. Both HAL and OLZ suppressed avoid-
ance responding on the first drug day, and this effect 
was potentiated with each subsequent drug test (a pro-
gressive across-session decline). Interestingly, on all 
drug-free retraining days, avoidance responding in both 
groups fully recovered back to the predrug levels. On 
the contrary, rats treated with vehicle maintained a high 
level of avoidance responding throughout the entire test-
ing period. This observation was confirmed by statistical 
analysis. A repeated measures ANOVA using ‘Drug Ses-
sion’ as a within-subject factor and ‘Treatment Group’ 
as a between-subjects factor showed a significant main 
effect of ‘Treatment Group’ (F(2,20) =20.724, P <0.001), 
‘Drug Session’ (F(6,120) = 14.017, P < 0.001), and a ‘Treat-
ment Group’ × ‘Drug Session’ interaction (F(2,20) =13.987, 
P < 0.001). Individual one-way ANOVAs and post hoc 
Tukey tests on each drug-testing day showed that the 
OLZ group differed significantly from the vehicle group 
on each day (Figure 1A, all Ps < 0.003), and HAL differed 
significantly from the vehicle group on days 4 through 7 
(all Ps < 0.05).
To examine the similarity between the HAL and OLZ-
induced drug state mediating avoidance, and whether 
previous antipsychotic treatment potentiated later 
response to HAL, all rats were treated with HAL (0.05 
mg/kg, s.c.) for three consecutive days 3 days after the 
last retraining test (see Figure 1B). An independent-sam-
ples T-test revealed the previously HAL-treated group 
showed significantly lower avoidance responses than the 
previously vehicle-treated group on days 1 and 2 (Day 1: 
t(13) = 3.443, P = 0.004, Day 2: t(13) = 2.412, P = 0.031), 
indicating a potentiated effect of previous HAL treat-
ment. The previously OLZ-treated group also differed 
significantly from the vehicle group on days 1 and 2 (Day 
1: t(13) = 2.879, P =0.021, Day 2: t(13) = 2.218, P = 0.045), 
suggesting that previous OLZ treatment also potentiated 
the HAL effect, and there was a similarity between the 
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HAL and OLZ-induced interoceptive states. The previ-
ously OLZ-and HAL-treated groups did not differ from 
each other on any day (all Ps > 0.05).
Experiment 2: Effects of OLZ treatment (0.5, 1.0 and 2.0 mg/
kg) during the avoidance training on later avoidance respond-
ing to OLZ (1.0 mg/kg)
OLZ treatment severely impaired the acquisition of 
avoidance responding. Rats repeatedly treated with 
three different doses of OLZ (0.5, 1.0, 2.0 mg/kg) during 
the acquisition phase of the CAR paradigm did not show 
any improvement in avoidance responding (Figure 2A). 
In contrast, rats treated with CDP, 10 mg/kg or vehicle
(distilled water) showed a steady improvement through-
out the training phase (repeated measures ANOVAs: a 
significant main effect of ‘Treatment’: F(4,40) = 15.489, P 
< 0.001; ‘Sessions’: F(6,240) = 3.506, P = 0.002; and ‘Treat-
ment’ × ‘Sessions’ interaction, F(24,240) = 5.745, P < 0.001). 
In the three subsequent drug-free CS-only test days, as 
shown in Figure 2B, the OLZ rats still showed signifi-
cantly lower avoidance responses than the other groups 
(all Ps < 0.05). Detailed analysis of avoidance response 
data was reported in Mead, et al. (2008).
After the 10 sessions of drug-free retraining, only those 
rats that exhibited more than 70% avoidances in the last 
two retraining sessions were used in the OLZ retests. As 
can be seen in Figure 3, before the OLZ treatment, both 
the OLZ experienced group and the nonexperienced 
group had almost identical mean avoidance responses. 
However, upon retesting, the rats with previous OLZ 
experience showed a much lower level of avoidance 
responding than those with no previous OLZ experience 
over the three test sessions. Independent-samples T-tests 
showed that there were significant differences on Day 1 
(t(33) = -5.536, P < 0.001), Day 2 (t(33) = -3.133, P = 0.006) 
and Day 3 (t(33) = -3.344, P = 0.004).
Experiment 3: Effects of RIS treatment (0.2, 0.33, and 1.0 mg/
kg) during the avoidance training on later avoidance respond-
ing to RIS (0.33 mg/kg)
Rats treated with 10 mg/kg of CDP), 10 mg/kg of CIT, 
or vehicle (distilled water) showed a steady improve-
ment throughout the training phase. RIS treatment dose 
dependently impaired the acquisition of avoidance 
responding as the RIS 1.0 group–but not RIS 0.2 and RIS 
0.33 groups–showed fewer avoidances than the vehicle 
group (Tukey HSD test, P < 0.001). In the three subse-
quent drug-free CS-only test days, as shown in Figure 4B,
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only the RIS 1.0 group showed significantly fewer avoid-
ance responses than the other drug groups (P <0.001).
After the 10 sessions of drug-free retraining, only those 
rats that exhibited more than 70% avoidances in the last 
two retraining sessions were used in the RIS retests. As 
can be seen in Figure 5, before the RIS treatment, both the 
RIS experienced group and the nonexperienced group 
had almost identical mean avoidance responses. How-
ever, upon retesting, the rats with previous RIS experi-
ence showed a much lower level of avoidance responding 
than those with no previous RIS experience. Indepen-
dent-samples T-tests showed that there was a significant
difference on Day 2 (t(43) = -2.089, P < 0.043), but not on 
Day 1 (t(43) = -1.528, P = 0.135) nor Day 3 (t(43) = -1.157, 
P = 0.254).
Discussion
Results from the three experiments provide additional 
support to the idea that antipsychotic-induced interocep-
tive state may be one of the important behavioral mech-
anisms underlying the potentiated antiavoidance effect 
of repeated antipsychotic treatments. In Experiment 1, 
we found that repeated intermittent antipsychotic treat-
ment could reliably produce an across-session decline 
in avoidance responding. Rats repeatedly treated with 
HAL and OLZ every 3rd day, still exhibit an across-ses-
sion decline despite the ability to return to high avoid-
ance levels in between drug treatments. In addition, we 
found that when rats were tested under HAL (0.03 mg/
kg), those previously treated with OLZ showed signifi-
cantly lower levels of avoidance responding than vehi-
cle rats, even though both groups were treated with 
HAL for the first time. In Experiments 2 and 3, rats pre-
viously treated with OLZ or RIS during the acquisition 
phase showed significantly fewer avoidance responses 
than those without such a drug experience during the 
retests 3 weeks later, suggesting that rats that have expe-
rienced an antipsychotic may ‘remember’ that drug state 
and respond accordingly. This increase of anti-avoidance 
effect across multiple drug test sessions does not seem to 
reflect simple drug accumulation effect, as the half-lives 
of antipsychotics in the rat brain is 1.5 h for HAL (Cheng 
and Paalzow, 1992), 2.5 h for OLZ (Aravagiri, et al., 1999), 
and less than 4 h for RIS (van Beijsterveldt, et al., 1994), 
and we observed that the progressively potentiated anti-
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avoidance effect persisted for at least 3 days (Experiment 
1) and over a 3-week period (Experiments 2 and 3).
In Experiment 1, we found that repeated intermittent 
HAL and OLZ treatment can reliably produce an across-
session decline in avoidance responding. This finding is 
consistent with one of the experiments reported in Li, et 
al. (2007). In that experiment, one group of well-trained 
rats (a within-subject design) received three doses of 
HAL from 0.03, 0.05, to 0.07 mg/kg (in this order) on 
an intermittent schedule, with drug-free retraining ses-
sions inserted between two drug sessions. The rats were 
then tested a second time under the same drug sched-
ule. The avoidance-disruptive effect of HAL at the same 
doses was much stronger in the 2nd round than in the 
1st round. However, several limitations from that experi-
ment prevent us from drawing a firm conclusion regard-
ing the role of the interoceptive drug state in the anti-
avoidance potentiation. First, the exact source of the 
potentiated antiavoidance response seen in the 2nd 
round is not clear. This is because a higher dose of HAL 
(e.g. 0.07 mg/kg) in the 1st round was always tested 
prior to a lower dose of HAL in the second round (e.g. 
0.03 mg/kg); thus, it is possible that the potentiated anti-
avoidance effect could be due to the repeated drug expe-
rience or due to the influence from the higher doses. 
Second, only HAL (a typical antipsychotic drug) was 
examined for the behavioral mechanism of antipsychotic 
action. Other anti-psychotics, such as atypicals like OLZ 
and RIS, were not examined. This study addressed these 
limitations, and the results suggest that even atypical 
drugs, such as OLZ and RIS, may work through a simi-
lar behavioral mechanism, e.g. by producing an antipsy-
chotic-like interoceptive drug state that allows the ani-
mals to respond according to the drug state. Our results 
are also consistent with recent reports by Samaha, et al. 
(2007, 2008) who found that repeated intermittent HAL 
treatment (e.g. daily injection) gained efficacy in disrupt-
ing avoidance responding across multiple sessions. What 
is even more remarkable with our findings is the fact that 
this potentiated efficacy persists even after rats were off 
drug for weeks and being retrained, so that their avoid-
ances were back at the pre-drug levels (see Figures 1A, 3, 
and 5). It appears that once a rat is exposed to an antipsy-
chotic drug, this drug experience stays with it for a long 
period of time, and this memory-like drug effect is pos-
sibly mediated by the drug-induced interoceptive state. 
Behaviorally, an antipsychotic drug may act as an occa-
sion setter (Maes and Vossen, 1997), which sets the con-
dition in which rats behave on the basis of their previ-
ous drug experience in the avoidance testing context, or 
it may directly imprint the brain to create a drug ‘mem-
ory trace’ about avoidance responding under drug. This 
proposition may explain why continuous HAL treatment 
through osmotic minipumps lost efficacy in disrupting 
avoidance responding (Samaha, et al., 2008; Samaha, et 
al., 2007), as continuous drug treatment could not create 
a discrete drug state that is time-locked with the avoid-
ance testing context. Thus, it may lose its occasion-setting 
property and not be able to direct animals’ behavior in the 
avoidance testing situation. Using dopamine D2 recep-
tor occupancy as a guide, Kapur, et al. (2003) suggests 
that antipsychotic administration through minipumps 
provides a better model of antipsychotic treatment in 
the clinic, as only this mode of drug administration pro-
duces clinical-relevant D2 occupancies (60-80%), a con-
dition found in patients with schizophrenia maintained 
on medications (Kapur, et al., 2003). On the basis of the 
current findings and that of Samaha, et al. (2007, 2008), 
it seems that although continuous drug administration 
provides a better model of pharmacodynamic and phar-
macokinetic actions (e.g. D2 occupancy) of antipsychotics 
than intermittent treatment, it may not provide a better 
model of behavioral effects of antipsychotics, which show 
a progressive enhancement over time (Agid, et al., 2003; 
Kapur, et al., 2005), and only intermittent drug treatment 
in rats produces such a pattern of effects (Li, et al., 2007; 
Sun, et al., 2009).
So what are the possible neural bases of the drug state-
based potentiated antipsychotic effect? We speculate that 
it may have something to do with the drug-induced brain 
changes, (e.g. neuroplasticity) because of its memory-
like characteristics (Konradi and Heckers, 2001). These 
changes thus, might include elevations in the number and 
sensitivity of neuroreceptors (e.g. D2, receptors) (Samaha, 
et al., 2008; Samaha, et al., 2007), changes in the imme-
diate early gene expressions (e.g. c-fos, zif268, (ΔFosB) 
(Grande, et al., 2004; Nguyen, et al., 1992; Robertson 
and Fibiger, 1992; Robertson, et al., 1994) and associated 
intracellular signaling pathways (e.g. DARPP-32, cAMP 
and PKA phosphorylation in the striatopallidal neurons) 
(Bateup, et al., 2008), or even adult neurogenesis (Kip-
pin, et al., 2005). This issue needs further investigation.
The idea that antipsychotic-induced interoceptive state 
may be an important mechanism underlying the poten-
tiated anti-avoidance effect with repeated treatment is 
also supported by the finding that rats that were previ-
ously treated with OLZ showed significantly lower lev-
els of avoidance responding when tested under HAL 
than the rats previously treated with vehicle, although 
both groups were exposed to HAL for the first time. This 
finding suggests that the antipsychotic-induced intero-
ceptive state is transferable between drugs that create 
a similar state (i.e. other antipsychotics with a differ-
ent structure and receptor profile). This finding is com-
plimentary to one of the findings from Li, et al. (2007). 
In that report, they found that rats previously treated 
with HAL continued to show the suppressed avoidance 
responding when switched to OLZ. Collectively, both 
findings suggest that there is a similarity between HAL 
and OLZ-induced antipsychotic-specific interoceptive 
state, as they can substitute for each other.
One prediction based on this drug (interoceptive state)-
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dependent memory mechanism is that even if the drug 
has been stopped and the avoidance responding has fully 
recovered back to the predrug level, during the next expo-
sure to antipsychotic treatment, the animals with a previ-
ous drug experience should show a greater response – a 
prediction that was confirmed for both OLZ (Experiment 
2) and RIS (Experiment 3). There is an interesting differ-
ential effect between the two widely prescribed drugs.
 During the avoidance training phase, OLZ impaired 
the acquisition of avoidance response at all three dosage 
levels, whereas RIS suppressed the avoidance acquisition 
only at the highest dosage level. During the drug retests, 
OLZ showed a stronger reexposure effect, as it caused 
a significant group difference on each of the three test 
sessions, whereas RIS showed a weaker effect as it only 
caused a significant group difference on the second ses-
sion. One possible explanation lies in the differences in the 
receptor binding profiles. OLZ has high affinity to dop-
amine D1, D2, D3, D4, serotonin 5-HT2, histaminic H1, α-1 
adrenergic and muscarinic M1-M5 receptors. RIS shows 
high affinity for D2 and 5-HT2A, as well as affinity for 
D1, D4, α-1 adrenergic, and α-2 adrenergic and histamine 
H1 receptors (Miyamoto, et al., 2005). The exact binding 
differences accounting for their differential potentiated 
effect in avoidance model are not clear and need future 
investigation. Another more likely explanation is the dif-
ference in the efficacy of OLZ and RIS doses used in the 
retests. OLZ at 1.0 mg/kg may be more efficacious than 
RIS at 0.33 mg/kg, thus, producing a stronger potentiated 
effect. This point is also supported by the finding that 
OLZ 1.0 mg/kg impaired the acquisition of avoidance 
response, whereas RIS 0.33 mg/kg did not. It is thus pos-
sible that, had we used a higher dose of RIS (e.g. 1.0 mg/
kg), we could have seen the same level of potentiation.
Clinical observations indicate that antipsychotic action 
starts early and increases in magnitude with repeated 
treatment (Agid, et al., 2003; Agid, et al., 2006; Emsley, 
et al., 2006; Glick, et al., 2006; Kapur, et al., 2005; Leucht, 
et al., 2005; Raedler, et al., 2007). However, animal mod-
els that faithfully capture this time course of action are 
few. This study represents an advance of our previous 
work (Li, et al., 2007) and further supports the idea that 
rat avoidance responding model based on the repeated 
drug treatment regimen is capable of mimicking sev-
eral important features of clinical effects of antipsychotic 
treatment. It also provides a clue on the behavioral mech-
anism of antipsychotic action in the treatment of schizo-
phrenia. Our previous work (Li, et al., 2007) and a recent 
one (Li, et al., accepted) suggest that antipsychotic drugs 
suppress avoidance responding by weakening the moti-
vational salience of the CS. This observation, together 
with the current findings, suggests that repeated antip-
sychotic treatment may disrupt avoidance responding 
by two distinct mechanisms: (a) weakening the motiva-
tional salience of the CS and (b) providing an interocep-
tive drug state that maintains the weakening effect on 
motivational salience of the CS over time. To carefully 
extrapolate to clinical treatment, we would propose a 
hypothesis that antipsychotic drugs may achieve their 
antipsychotic effect through a dual action: (a) selectively 
weakening the aberrant motivational salience of stimuli 
(e.g., psychotic thoughts or abnormal perceptions, inter-
nal and external cues) (Kapur, 2003); and (b) producing a 
drug interoceptive state that allows the weakening effect 
on the motivational salience of stimuli to be maintained 
over time. Practically, this study may also provide sup-
port for the intermittent drug treatment regimen to be 
tried in the clinic. Currently, the most common practice 
in the clinic is to treat patients with antipsychotics on the 
daily basis which produces approximately 60%-80% of 
dopamine D2 receptor occupancy (Kapur, 1998). As it is 
widely known that antipsychotic treatment carries many 
side effects, including EPS and excess weight gain, an 
intermittent schedule may be an efficient and safer alter-
native warranting further research. A recent study shows 
that dosing every 2-3 days is sufficient to maintain antip-
sychotic efficacy in schizophrenic patients (Remington, 
et al., 2005). These findings may suggest that upon ini-
tial exposure, physiological events may be initiated that 
enhance the antipsychotic’s effects beyond its presence 
at the receptor, thereby not requiring constant binding at 
the receptor every day to be efficacious.
In summary, this study confirms that repeated antipsy-
chotic treatment induces an interoceptive drug state that 
mediates the potentiated antiavoidance effect of antip-
sychotics (HAL, OLZ and RIS) over multiple drug test 
sessions. This drug state-dependent ‘memory-like’ mech-
anism allows animals to make avoidance responses 
according to the drug state that they experience and can 
last for weeks. This mechanism may also be responsi-
ble for the clinical effects of repeated antipsychotic treat-
ments in schizophrenia.
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